Company intelligence / Profile preview

VGX Animal Health

Blue Bell, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

VGX Animal Health achieved regulatory approval for LifeTide SW 5 in Australia in January 2008, making it the world's first therapeutic plasmid delivered by electroporation approved for food animals. The product demonstrated significant decreases in perinatal mortality and morbidity in sows. Preclinical studies showed their TERT DNA vaccine delayed tumor growth and increased survival in mice, and their GHRH plasmid technology was effective in increasing daily lean weight gain in piglets with a single treatment versus daily growth hormone injections.

Therapeutic areas: NephrologyRheumatologyInfectious DiseasesHematologyOtherOncology
Modalities: DNA vaccinePlasmid-based therapyGene therapy
Industry: Veterinary

Partnerships

Plumbline Life Sciences

Beyond the preview

Go deeper on VGX Animal Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGX Animal Health.

Explore the full profile